Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1986 1
1987 1
1989 1
1990 2
1991 1
1992 4
1993 3
1994 4
1995 4
1996 5
1997 2
2002 1
2004 1
2006 1
2008 1
2009 5
2010 5
2011 3
2012 5
2013 5
2014 4
2015 3
2016 7
2017 6
2018 2
2019 9
2020 7
2021 12
2022 4
2023 11
2024 5
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Makker V, et al. Among authors: messing m. J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. J Clin Oncol. 2020. PMID: 32167863 Free PMC article. Clinical Trial.
Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease.
Freitag TL, Podojil JR, Pearson RM, Fokta FJ, Sahl C, Messing M, Andersson LC, Leskinen K, Saavalainen P, Hoover LI, Huang K, Phippard D, Maleki S, King NJC, Shea LD, Miller SD, Meri SK, Getts DR. Freitag TL, et al. Among authors: messing m. Gastroenterology. 2020 May;158(6):1667-1681.e12. doi: 10.1053/j.gastro.2020.01.045. Epub 2020 Feb 4. Gastroenterology. 2020. PMID: 32032584 Free PMC article.
In-Flight Tuning of Au-Sn Nanoparticle Properties.
Ternero P, Preger C, Eriksson AC, Rissler J, Hübner JM, Messing ME. Ternero P, et al. Among authors: messing me. Langmuir. 2024 Aug 6;40(31):16393-16399. doi: 10.1021/acs.langmuir.4c01656. Epub 2024 Jul 26. Langmuir. 2024. PMID: 39058950 Free PMC article.
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS, Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJ. Makker V, et al. Among authors: messing mj. J Immunother Cancer. 2024 Jan 19;12(1):e007929. doi: 10.1136/jitc-2023-007929. J Immunother Cancer. 2024. PMID: 38242717 Free PMC article.
Compositional tuning of gas-phase synthesized Pd-Cu nanoparticles.
Franzén SM, Jönsson L, Ternero P, Kåredal M, Eriksson AC, Blomberg S, Hübner JM, Messing ME. Franzén SM, et al. Among authors: messing me. Nanoscale Adv. 2023 Sep 6;5(22):6069-6077. doi: 10.1039/d3na00438d. eCollection 2023 Nov 7. Nanoscale Adv. 2023. PMID: 37941940 Free PMC article.
124 results